This article is more than 5 years old. Information may no longer be current.
Oral anti-VEGF, anti-PDGF advanced in pipeline of wet AMD treatments
LAS VEGAS — Early data from study of orally administered X-82 show promise for treating wet age-related macular degeneration, according to a presentation here.
X-82 (Tyrogenex) is a tyrosine kinase inhibitor (TKI) with both anti-VEGF and anti- platelet-derived growth factor (PDGF) activities.
Nauman A. Chaudhry, MD, presented data from a phase 1 open-label study of 35 patients with wet AMD, in which six treatment regimens at four dose levels of X-82 were evaluated for preliminary safety and efficacy.
Both refractory and treatment naïve patients maintained or improved vision with few or no intravitreal injections needed. No dose-limiting toxicities were found.
Additionally, there was significant proof-of-concept improvement in OCT images and visual acuity outcomes.
The phase 1 trial results support the randomized, double-masked, comparative dose and placebo-controlled phase 2 study of daily dosing of X-82, which is currently underway, Chaudhry said. — by Kristie L. Kahl
Reference:
Chaudhry NA. Oral VEGF receptor/PDGF receptor inhibitor X-82. Presented at: The Academy of Ophthalmology. Nov. 13, 2015; Las Vegas.
Disclosure:
Chaudhry reports he is an equity owner of Eye Formatics.